

REMARKS

Applicants have amended the Application as indicated above, on the recited pages to correct inadvertent errors. Specifically, claim 4 has been amended to remain consistent with Examiner's amendments of the Notice of Allowance dated March 9, 2006, reflecting "pharmaceutically acceptable" salts. In addition, the reaction schemes of pages 23, 26, 28, 29, and 31 have been amended to accurately reflect the reaction reagents as indicated therein. Applicants respectfully submit that each of the above amendments adds no new matter and finds adequate support in the specification.

The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. **18-1982** in the name of Aventis Pharmaceuticals Inc.

Respectfully submitted,

Date June 19, 2007

Robert J. Kajubi
Robert J. Kajubi, 55,312
Attorney for Applicants

sanofi-aventis Inc. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231- 3115
Telefax (908) 231-2626
sanofi-aventis Docket No. DEAV2002/0063 US NP